Effectiveness of nifedipine and deflazacort in the management of distal ureter stones

被引:184
作者
Porpiglia, F [1 ]
Destefanis, P [1 ]
Fiori, C [1 ]
Fontana, D [1 ]
机构
[1] Univ Turin, San Luigi Hosp, Dipartimento Clin & Biol, Div Univ Urol, I-10043 Turin, Italy
关键词
D O I
10.1016/S0090-4295(00)00732-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the effectiveness of medical therapy during watchful waiting in patients with distal ureter stones. Methods. Ninety-six patients with radiopaque stones located in the distal tract of the ureter and with stone sizes of 1 cm or smaller were involved in the study. The patients were randomly divided into two groups. Group A (n = 48) received oral treatment with 30 mg of deflazacort daily (maximum 10 days) plus 30 mg of slow-release nifedipine daily (maximum 4 weeks). Group B (n = 48) underwent a wait-and-watch approach. Both groups of patients were allowed to use diclofenac on demand. Statistical analyses were carried out using Student's t test, the chi-square test, and Fisher's exact test. Results. The average stone size was 5.8 +/- 1.8 mm for group A and 5.5 +/- 1.4 mm for group B. No statistically significant difference was found in stone size. Stone expulsion was observed in 38 (79%) of 48 patients in group A and in 17 (35%) of 48 patients in group B. The average expulsion time was 7 days (range 2 to 10) for group A and 20 days (range 10 to 28) for group B. A statistically significant difference was observed in both the expulsion rate and the expulsion time (P <0.05). The mean amount of sodium diclofenac used was 15 mg per patient for group A and 105 mg per patient for group B (P <0.05). Conclusions. The medical treatment proved to be effective and safe, as demonstrated by the increased stone expulsion rate, decreased expulsion time, and reduced need for analgesic therapy. UROLOGY 56: 579-583, 2000. (C) 2000, Elsevier Science Inc.
引用
收藏
页码:579 / 582
页数:4
相关论文
共 22 条
[1]  
ANDERSSON KE, 1986, ACTA PHARMACOL TOX, V58, P193
[2]   Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects [J].
Babadjanova, G ;
Allolio, B ;
Vollmer, M ;
Reincke, M ;
Schulte, HM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :53-57
[3]   NIFEDIPINE AND METHYLPREDNISOLONE IN FACILITATING URETERAL STONE PASSAGE - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
BORGHI, L ;
MESCHI, T ;
AMATO, F ;
NOVARINI, A ;
GIANNINI, A ;
QUARANTELLI, C ;
MINEO, F .
JOURNAL OF UROLOGY, 1994, 152 (04) :1095-1098
[4]  
Capecchi S, 1991, Minerva Urol Nefrol, V43, P287
[5]  
Carstensen H E, 1973, Acta Chir Scand Suppl, V433, P66
[6]  
COPENS L, 1986, ANN INTERN MED, V105, P967
[7]  
FETTER TR, 1963, JAMA-J AM MED ASSOC, V182, P127
[8]  
HANNAPPEL J, 1986, UROLOGE A, V25, P246
[9]   FREQUENCY OF UROLITHIASIS IN A PREPAID MEDICAL-CARE PROGRAM [J].
HIATT, RA ;
DALES, LG ;
FRIEDMAN, GD ;
HUNKELER, EM .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1982, 115 (02) :255-265
[10]  
Holmlund D, 1965, Acta Chir Scand, V130, P335